Exelixis, Genentech Strike Drug Development Pact

Drug developer Exelixis Wednesday it agreed to develop cancer drug candidate XL518 with biotech drug maker Genentech.


Under the agreement, Exelixis stands to receive $40 million in upfront and milestone payments. In December, Exelixis filed with the Food and Drug Administration to begin clinical trials for XL518, a novel small molecule drug designed to inhibit MEK, a substance that is key in the growth of tumor cells when improperly activated.

The company will be responsible for developing the drug through early-stage clinical trials.

Genentech can exercise an option to further develop the compound and will provide Exelixis with additional payments as well as development costs.

Exelixis has the option of selling any resulting product from the development agreement. Exelixis will be entitled to an equal share of the profits for U.S. sales, a share that will diminish as sales increase, and royalties for sales outside the U.S.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • CNBC's Mandy Drury looks back at the week's top business and financial stories. The jobs number was strong, but wages still lagged. And Lumber Liquidators took a big hit after a 60 Minutes report on laminates made in China. And AT&T is booted from the Dow in favor of Apple.

  • CNBC and Inc. bring together some of the country's most influential entrepreneurs to talk about innovation, inspiration, and becoming ICONIC.

  • Has the cold got your down? Pick yourself back up with a much-needed vacation, the hassle-free way. Travel & Leisure News Editor Amy Farley picks the best apps and websites for fool-proof booking on a dime.